“The Company’s projections of future Royalty Payments are subject to significant estimation uncertainty and are based on various assumptions, including expected commercial launch timelines, regulatory approval probabilities, and projected net product sales ove…”10-Q · May 6, 2026 ↗
Revolution Medicines, Inc.
RVMD
Market read
Revolution Medicines, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.
- Interest expense tied to the Royalty Purchase Agreement increased by $12.2 million in the three months ended March 31, 2026 versus the same period in 2025.
Invalidation: The isolated read changes if RVMD's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 37 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 13 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- Interest expense tied to the Royalty Purchase Agreement increased by $12.2 million in the three months ended March 31, 2026 versus the same period in 2025.
Company research
Understand the business, not just the ticker
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
- Credit and interest rates has repeated favorable evidence across 3 filings.
- Diluted shares increased 13.3% in the latest annual period.
No credible peer-relative valuation comparison is available yet.
Price as of Sep 11, 2026
203.82Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
Persistent and emerging business drivers
“Stock-based compensation expense Total stock-based compensation expense related to stock options, RSUs and the ESPP by function was as follows: Three Months Ended March 31, 2026 2025 (in thousands) Research and development $ 44,638 $ 16,380 General and admini…”10-Q · May 6, 2026 ↗
“Interest expense Interest expense increased by $12.2 million during the three months ended March 31, 2026 compared to the same period in 2025, reflecting non-cash interest expense and amortization of issuance costs associated with the Royalty Purchase Agreeme…”10-Q · May 6, 2026 ↗
“The increase for the nine months ended September 30, 2025 was primarily due to a $2.8 million impairment of a long term asset acquired as part of the EQRx Acquisition in the first quarter of 2024.”10-Q · Nov 5, 2025 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales — · EV/sales —. Comparisons use only industry-matched filing peers.
No usable price/earnings or price/sales multiple (need a fresh price).
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 15:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for RVMD. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for RVMD. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind RVMD
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
TNGXTango Therapeutics, Inc.partnerMay 6, 2026 ▾
“Tango Collaboration 80 In November 2024, we entered into a clinical collaboration with Tango Therapeutics, Inc.”
SNYSanofipartnerFeb 25, 2026 ▾
“Sanofi collaboration agreement In June 2018, the Company entered into a collaborative research, development and commercialization agreement (the Sanofi Agreement) with Aventis, Inc.”
Depended on by
TNGXTango Therapeutics, Inc.partnerMay 13, 2026 ▾
“Clinical Trial Collaboration and Supply Agreements In November 2024, the Company and Revolution Medicines, Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 17 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
RVMD is currently a Follower in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
This group is retained as the last observed read for RVMD; it is not active in the latest market snapshot.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.